Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences (Nasdaq: SGHT), an eyecare technology company, will release its Q2 2025 financial results on August 7, 2025, after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results.
Investors can access the live webcast and replay of the event through the company's website at www.sightsciences.com in the Investors section under News & Events. The webcast replay will be available for at least 90 days following the event.
Sight Sciences (NASDAQ: SGHT), an eyecare technology company specializing in innovative interventional technologies, has announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management will deliver a presentation on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Investors and interested parties can access both the live and archived versions of the fireside chat through the Investors section of Sight Sciences' website at investors.sightsciences.com.
The company focuses on developing and commercializing technologies aimed at transforming care and enhancing patients' lives in the eyecare sector.Sight Sciences (Nasdaq: SGHT), an eyecare technology company specializing in innovative interventional technologies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results for the quarter ended March 31, 2025. Investors can access the live webcast and replay (available for 90 days) through the company's website at www.sightsciences.com in the Investors page under News & Events section.
Sight Sciences (Nasdaq: SGHT) has released its second annual Sustainability Report, covering environmental, social, and governance initiatives from 2022 through 2024. The eyecare technology company reported significant environmental metrics, including Scope 1 emissions of 7,655 kg CO₂, Scope 2 emissions of 32,125 kg CO₂, and partial Scope 3 emissions of 2,169,524 kg CO₂.
Key social achievements include:
- Donations to 27 programs supporting indigent care across 18+ countries
- Reduced voluntary staff turnover from 19% to 14%
- Workforce diversity with 50%+ female employees
- Women in management positions increased to 39%
- Strong pay equity with women earning 95-110% compared to male counterparts
The company, employing 220 people globally, expanded its Women in Leadership initiative through a mentoring pilot project. The report demonstrates Sight Sciences' commitment to sustainability, transparency, and maintaining strong environmental, social, and corporate governance practices.
Sight Sciences (Nasdaq: SGHT) has appointed Gerhard (Gary) F. Burbach to its Board of Directors as a Class II director, with a term expiring at the 2026 Annual Meeting of Stockholders. The appointment was made on April 21, 2025.
Burbach brings extensive medtech industry experience, notably as former CEO of Thoratec , where he led the development of mechanical circulatory assist devices. He currently serves on the Board of Directors of BWX Technologies and as Chairman of Procyrion Inc. His expertise will support Sight Sciences' focus on maintaining leadership in surgical glaucoma and achieving market access in the dry eye segment.
The appointment comes at a strategic time as both glaucoma and dry eye markets are shifting towards interventional care, representing significant growth opportunities for the eyecare technology company.
Sight Sciences (SGHT) has announced the launch of OMNI® Edge Surgical System, expanding its OMNI® product portfolio. The new system will debut at the 2025 ASCRS Annual Meeting in Los Angeles.
The OMNI Edge features TruSync™ technology and increased viscoelastic capacity of 21 µL, nearly double the previous 11 µL capacity. The system is designed for minimally invasive glaucoma surgery (MIGS) and treats all three resistance areas in the aqueous outflow system: trabecular meshwork, Schlemm's canal, and collector channels.
The device maintains the trusted safety and usability of the original OMNI system while introducing synchronized viscoelastic delivery with surgeon rotation. It can be used as a standalone procedure or combined with cataract surgery for primary open-angle glaucoma (POAG) treatment. With over 300,000 procedures performed, OMNI has established itself as a leader in canal-based MIGS.
Sight Sciences (Nasdaq: SGHT), an eyecare technology company specializing in innovative interventional technologies, has announced its participation in the 24th Annual Needham Healthcare Conference. The virtual event will feature a presentation by the company's management on April 8, 2025, at 12:45 PM PT / 3:45 PM ET.
Investors and interested parties can access both the live and archived versions of the fireside chat through the company's investor relations website at investors.sightsciences.com.
Sight Sciences (SGHT) reported Q4 2024 revenue of $19.1M, up 2% YoY, while full-year 2024 revenue decreased 1% to $79.9M. The company's Surgical Glaucoma segment revenue grew 9% to $18.8M in Q4, while Dry Eye revenue declined to $0.3M from $1.6M YoY.
Q4 gross margin improved to 87% from 85% YoY. Full-year operating expenses decreased 6% to $118.8M, with net loss improving to $51.5M ($1.03 per share) from $55.5M ($1.14 per share) in 2023. Cash position stood at $120.4M as of December 31, 2024.
For 2025, SGHT projects revenue between $70-75M, representing a 6-12% decline, primarily due to Medicare LCD restrictions on multiple MIGS procedures during cataract surgery. The company expects adjusted operating expenses of $105-107M for 2025, a 4-6% increase from 2024.
Sight Sciences (SGHT) announced multiple presentations featuring the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting. A meta-analysis of 22 studies with 2,379 eyes demonstrated the system's effectiveness in reducing intraocular pressure and medication dependency for up to 36 months.
Key findings from the IRIS® Registry, one of the largest specialty clinical data registries, showed significant clinical outcomes across diverse patient populations. The data revealed that MIGS procedures using OMNI, when combined with cataract surgery in Black patients, resulted in significant IOP reductions through 24 months and medication reductions through 36 months.
The studies demonstrated favorable efficacy and safety profiles across different glaucoma severity levels, including standalone treatments in both phakic and pseudophakic eyes.